Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: An application using a Bayesian random change-point model

Haitao Chu; Stephen J. Gange; Traci E. Yamashita; Donald R. Hoover; Joan S. Chmiel; Joseph B. Margolick; Lisa P. Jacobson

doi:10.1093/aje/kwi268

Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: An application using a Bayesian random change-point model

Haitao Chu, Stephen J. Gange, Traci E. Yamashita, Donald R. Hoover, Joan S. Chmiel, Joseph B. Margolick, Lisa P. Jacobson

Biostatistics

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

The authors evaluated population- and individual-level CD4-positive T-lymphocyte (CD4 cell) count trajectories over a 7-year period (July 1995-March 2004) following initiation of highly active antiretroviral therapy (HAART) in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. The study population included 404 human immunodeficiency virus (HIV)-infected men and 609 HIV-infected women who 1) had a CD4 cell count measurement available from their last pre-HAART study visit, 2) provided at least four post-HAART CD4 cell count measurements, and 3) reported HAART usage for at least 80% of the post-HAART visits. The CD4 cell count trajectory was analyzed by means of a Bayesian random change-point model. The results indicated that CD4 cell count trajectories for long-term frequent HAART users can be well modeled with change points at both the population and individual levels. At the population level, regardless of CD4 cell count before HAART initiation, the gains in CD4 cell count ended approximately 2 years after HAART initiation in both men and women. At the individual level, 35% of men in the Multicenter AIDS Cohort Study versus 25% of women in the Women's Interagency HIV Study had a statistically significant change in CD4 cell count trajectory within 7 years after HAART initiation.

Original language	English (US)
Pages (from-to)	787-797
Number of pages	11
Journal	American journal of epidemiology
Volume	162
Issue number	8
DOIs	https://doi.org/10.1093/aje/kwi268
State	Published - Oct 2005

Bibliographical note

Funding Information:
Data presented in this paper were collected by the Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS) Collaborative Study Group. The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute, and the National Heart, Lung, and Blood Institute (grants UO1-AI-35042, 5-M01-RR-00052 (General Clinical Research Center), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, and UO1-AI-35041). The WIHS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute; the National Institute of Child Health and Human Development; the National Institute on Drug Abuse; the National Institute of Craniofacial and Dental Research; and the National Heart, Lung, and Blood Institute (grants U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-HD-32632, U01-AI-34993, U01-AI-42590, M01-RR00079, and M01-RR00083).

Keywords

Antiretroviral therapy, highly active
Bayes theorem
CD4 lymphocyte count
Change point
HIV infections
Models, statistical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1093/aje/kwi268

Find It

Find It at U of M Libraries

Fingerprint

Dive into the research topics of 'Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: An application using a Bayesian random change-point model'. Together they form a unique fingerprint.

Cite this

Chu, H., Gange, S. J., Yamashita, T. E., Hoover, D. R., Chmiel, J. S., Margolick, J. B., & Jacobson, L. P. (2005). Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: An application using a Bayesian random change-point model. American journal of epidemiology, 162(8), 787-797. https://doi.org/10.1093/aje/kwi268

Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: An application using a Bayesian random change-point model. / Chu, Haitao; Gange, Stephen J.; Yamashita, Traci E. et al.
In: American journal of epidemiology, Vol. 162, No. 8, 10.2005, p. 787-797.

Research output: Contribution to journal › Article › peer-review

Chu, H, Gange, SJ, Yamashita, TE, Hoover, DR, Chmiel, JS, Margolick, JB & Jacobson, LP 2005, 'Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: An application using a Bayesian random change-point model', American journal of epidemiology, vol. 162, no. 8, pp. 787-797. https://doi.org/10.1093/aje/kwi268

Chu H, Gange SJ, Yamashita TE, Hoover DR, Chmiel JS, Margolick JB et al. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: An application using a Bayesian random change-point model. American journal of epidemiology. 2005 Oct;162(8):787-797. doi: 10.1093/aje/kwi268

@article{420540c34e5c472e9e4eecd6033e759b,

title = "Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: An application using a Bayesian random change-point model",

abstract = "The authors evaluated population- and individual-level CD4-positive T-lymphocyte (CD4 cell) count trajectories over a 7-year period (July 1995-March 2004) following initiation of highly active antiretroviral therapy (HAART) in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. The study population included 404 human immunodeficiency virus (HIV)-infected men and 609 HIV-infected women who 1) had a CD4 cell count measurement available from their last pre-HAART study visit, 2) provided at least four post-HAART CD4 cell count measurements, and 3) reported HAART usage for at least 80% of the post-HAART visits. The CD4 cell count trajectory was analyzed by means of a Bayesian random change-point model. The results indicated that CD4 cell count trajectories for long-term frequent HAART users can be well modeled with change points at both the population and individual levels. At the population level, regardless of CD4 cell count before HAART initiation, the gains in CD4 cell count ended approximately 2 years after HAART initiation in both men and women. At the individual level, 35% of men in the Multicenter AIDS Cohort Study versus 25% of women in the Women's Interagency HIV Study had a statistically significant change in CD4 cell count trajectory within 7 years after HAART initiation.",

keywords = "Antiretroviral therapy, highly active, Bayes theorem, CD4 lymphocyte count, Change point, HIV infections, Models, statistical",

author = "Haitao Chu and Gange, {Stephen J.} and Yamashita, {Traci E.} and Hoover, {Donald R.} and Chmiel, {Joan S.} and Margolick, {Joseph B.} and Jacobson, {Lisa P.}",

note = "Funding Information: Data presented in this paper were collected by the Multicenter AIDS Cohort Study (MACS) and the Women{\textquoteright}s Interagency HIV Study (WIHS) Collaborative Study Group. The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute, and the National Heart, Lung, and Blood Institute (grants UO1-AI-35042, 5-M01-RR-00052 (General Clinical Research Center), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, and UO1-AI-35041). The WIHS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute; the National Institute of Child Health and Human Development; the National Institute on Drug Abuse; the National Institute of Craniofacial and Dental Research; and the National Heart, Lung, and Blood Institute (grants U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-HD-32632, U01-AI-34993, U01-AI-42590, M01-RR00079, and M01-RR00083).",

year = "2005",

month = oct,

doi = "10.1093/aje/kwi268",

language = "English (US)",

volume = "162",

pages = "787--797",

journal = "American journal of epidemiology",

issn = "0002-9262",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy

T2 - An application using a Bayesian random change-point model

AU - Chu, Haitao

AU - Gange, Stephen J.

AU - Yamashita, Traci E.

AU - Hoover, Donald R.

AU - Chmiel, Joan S.

AU - Margolick, Joseph B.

AU - Jacobson, Lisa P.

N1 - Funding Information: Data presented in this paper were collected by the Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS) Collaborative Study Group. The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute, and the National Heart, Lung, and Blood Institute (grants UO1-AI-35042, 5-M01-RR-00052 (General Clinical Research Center), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, and UO1-AI-35041). The WIHS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute; the National Institute of Child Health and Human Development; the National Institute on Drug Abuse; the National Institute of Craniofacial and Dental Research; and the National Heart, Lung, and Blood Institute (grants U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-HD-32632, U01-AI-34993, U01-AI-42590, M01-RR00079, and M01-RR00083).

PY - 2005/10

Y1 - 2005/10

N2 - The authors evaluated population- and individual-level CD4-positive T-lymphocyte (CD4 cell) count trajectories over a 7-year period (July 1995-March 2004) following initiation of highly active antiretroviral therapy (HAART) in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. The study population included 404 human immunodeficiency virus (HIV)-infected men and 609 HIV-infected women who 1) had a CD4 cell count measurement available from their last pre-HAART study visit, 2) provided at least four post-HAART CD4 cell count measurements, and 3) reported HAART usage for at least 80% of the post-HAART visits. The CD4 cell count trajectory was analyzed by means of a Bayesian random change-point model. The results indicated that CD4 cell count trajectories for long-term frequent HAART users can be well modeled with change points at both the population and individual levels. At the population level, regardless of CD4 cell count before HAART initiation, the gains in CD4 cell count ended approximately 2 years after HAART initiation in both men and women. At the individual level, 35% of men in the Multicenter AIDS Cohort Study versus 25% of women in the Women's Interagency HIV Study had a statistically significant change in CD4 cell count trajectory within 7 years after HAART initiation.

AB - The authors evaluated population- and individual-level CD4-positive T-lymphocyte (CD4 cell) count trajectories over a 7-year period (July 1995-March 2004) following initiation of highly active antiretroviral therapy (HAART) in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. The study population included 404 human immunodeficiency virus (HIV)-infected men and 609 HIV-infected women who 1) had a CD4 cell count measurement available from their last pre-HAART study visit, 2) provided at least four post-HAART CD4 cell count measurements, and 3) reported HAART usage for at least 80% of the post-HAART visits. The CD4 cell count trajectory was analyzed by means of a Bayesian random change-point model. The results indicated that CD4 cell count trajectories for long-term frequent HAART users can be well modeled with change points at both the population and individual levels. At the population level, regardless of CD4 cell count before HAART initiation, the gains in CD4 cell count ended approximately 2 years after HAART initiation in both men and women. At the individual level, 35% of men in the Multicenter AIDS Cohort Study versus 25% of women in the Women's Interagency HIV Study had a statistically significant change in CD4 cell count trajectory within 7 years after HAART initiation.

KW - Antiretroviral therapy, highly active

KW - Bayes theorem

KW - CD4 lymphocyte count

KW - Change point

KW - HIV infections

KW - Models, statistical

UR - http://www.scopus.com/inward/record.url?scp=26444511233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444511233&partnerID=8YFLogxK

U2 - 10.1093/aje/kwi268

DO - 10.1093/aje/kwi268

M3 - Article

C2 - 16135508

AN - SCOPUS:26444511233

SN - 0002-9262

VL - 162

SP - 787

EP - 797

JO - American journal of epidemiology

JF - American journal of epidemiology

IS - 8

ER -

Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: An application using a Bayesian random change-point model

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this